A sensitive solution-hybridization assay was used to investigate the expression of genes encoding insulin-like growth factors I and II (IGF-I and -I) in the rat central nervous system (CNS). mRNAs for both IGFs are synthesized throughout the CNS of adult rats but exhibit distinct regional differences for each growth factor. IGF-I mRNA is 8-10 times more abundant in the cervical-thoracic spinal cord and in the olfactory bulb than in whole brain and is enriched 3-fold in the midbrain and cerebellum. IGF-U mRNA is minimally enriched in the medulla-pons and cerebellum but is 3-5 times less abundant in the midbrain and corpus striatum than in total brain. During CNS development the content of IGF-I and IGF-II mRNAs is highest at embryonic day 14 and declines by a factor of 3-4 at birth, to values found in adult brain. Embryonic neurons and glia synthesize IGF-I mRNA during short-term cell culture; only glia produce IGF-II mRNA. These observations show that IGF-I and IGF-il are differentially expressed in the developing and adult CNS and suggest that each growth factor may play a unique role in the mammalian nervous system. The insulin-like growth factors (IGFs), or somatomedins, are polypeptide mitogens that play fundamental roles in mammalian growth processes. IGF-I (somatomedin C), a basic peptide of 70 amino acids (1), is the major mediator through which growth hormone exerts its biological effects on postnatal growth (2-4). IGF-II, a 67-residue neutral protein (5), may perform comparable growth-promoting functions during fetal life (2, 3). Both IGFs have been found in a variety of tissues, including the brain (6-16), although the precise physiological roles of either IGF in the central nervous system (CNS) are undefined.
The insulin-like growth factors (IGFs), or somatomedins, are polypeptide mitogens that play fundamental roles in mammalian growth processes. IGF-I (somatomedin C), a basic peptide of 70 amino acids (1) , is the major mediator through which growth hormone exerts its biological effects on postnatal growth (2) (3) (4) . IGF-II, a 67-residue neutral protein (5) , may perform comparable growth-promoting functions during fetal life (2, 3) . Both IGFs have been found in a variety of tissues, including the brain (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , although the precise physiological roles of either IGF in the central nervous system (CNS) are undefined.
Recent evidence suggests that both somatomedins may be involved in several aspects of neural metabolic and growth processes. Receptors for IGF-I are widely distributed throughout the mammalian CNS (17) (18) (19) . A specific subtype of the IGF-I receptor with a modified a subunit appears to be expressed on neurons (18) . Presumably through this highaffinity receptor IGF-I is able to enhance RNA synthesis in neurons (18) , stimulate DNA synthesis in embryonic brain cells in vitro (20) , and support the differentiation of cortical neurons (21) . A glial subtype similar to the receptor on peripheral tissues (18) may mediate the effects of IGF-I on oligodendrocyte proliferation (22) .
The IGF-II receptor also is found throughout the CNS (17) . Like IGF-I, IGF-II appears able to function as a neuronal growth factor, promoting the survival and differentiation of embryonic chicken sensory and sympathetic neurons in primary culture (23, 24) and inducing neurite outgrowth in cultured human neuroblastoma cell lines (25) .
Although these studies suggest that somatomedins may be trophic factors or neuromodulators in the brain or spinal cord, it is not known where the IGFs are produced in the nervous system and thus whether they may be considered as autocrine or paracrine growth-promoting agents for specific regions of the CNS. To (28) . Morphological appearance and celltype-specific staining for glial fibrillary acidic protein indicated that these cultures were >80% astroglia.
Molecular Cloning. The gene encoding rat IGF-I was isolated as a series of overlapping clones from two rat chromosomal libraries in bacteriophage X as described (29) . The gene specifying rat IGF-II was isolated similarly from a chromosomal library (30) and was characterized by restric- tion endonuclease mapping and partial DNA sequencing. A recombinant plasmid containing rat IGF-I exon 3 was prepared in pGEM-1 (Promega Biotec, Madison, WI), and a subclone consisting of most of the first protein-coding exon of rat IGF-II and adjacent intron sequences was prepared in pBS (Stratagene, San Diego, CA). Plasmids were grown in Escherichia coli K-12 strain DH1 (31) and isolated from a cleared lysate (32) . The orientation and identity of each recombinant were verified by restriction enzyme digestion.
RNA Isolation. Total cellular RNA was prepared as described by Chirgwin et al. (33) , from freshly isolated organs or cell pellets by homogenization in guanidinium thiocyanate and centrifugation through a gradient of CsCl. The integrity of each RNA sample was verified by gel electrophoresis, and the quantity was determined spectrophometrically.
RNA Analysis. A solution-hybridization nuclease-protection assay using 8 gg of total cellular RNA was performed as described (34 RESULTS Detection of IGF-Specific mRNAs. Before examining the distribution of IGF-I and -II mRNAs in the CNS, we sought to establish the specificity and sensitivity of a solutionhybridization assay that employed as probes single-stranded fragments derived from protein-coding exons of the two rat IGF genes (Fig. 1) . We first determined that each probe recognized on gel blots of liver RNA the appropriate pattern of multiple mRNA species unique to each growth factor (9-11, 13-16); we then defined the limits of detection by solution hybridization. The IGF-I probe, consisting of a 956-base genomic restriction fragment containing the 182-base exon 3, hybridizes to typically seen mRNAs of 7.8, 1.6-2.0, and 1.0-1.4 kilobases (9, 14-16) in adult liver poly(A)+ RNA (Fig. 2, lane 2) . Only the 1.6 to 2.0-kb mRNAs are detected in total RNA (lane 1). Similarly, the 720-base IGF-II probe, which contains 152 bases of exon 1, hybridizes to a characteristic mRNA of 4.0 kb, as well as to other minor species (9-14) in 21-day fetal liver RNA (lanes 3 and 4).
Having established the specificity of the IGF-I and IGF-II probes by gel-blot hybridization, we next defined the sensitivity and specificity of the solution-hybridization nucleaseprotection assay. As seen in Fig. 3 , by this approach IGF-I mRNA could be detected readily in 0.1 ug of total liver RNA from adult rats, and IGF-II mRNA in 0. RNA, an increase in sensitivity of >2 orders of magnitude compared with gel blotting. In a denaturing polyacrylamide gel the protected IGF-I band migrates as a single fragment of 182 nucleotides, the precise size ofexon 3, further confirming the specificity of the assay. Under similar conditions the protected IGF-II fragment appears as a doublet of 151-152 bases, corresponding to the 152 nucleotides of exon 1 encoded by the probe (Figs. 1 and 3 ). Both IGF-I and IGF-II assays showed a linear increase in signal with increasing input of tissue RNA (Fig. 3 and data not shown). for each growth factor (Fig. 4) . IGF-I mRNA was found predominantly in the cervical-thoracic spinal cord and in the olfactory bulb, being 8-to 10-fold more abundant than in the whole brain. Levels in midbrain and cerebellum were enriched t3-fold, while in cortex, corpus striatum, hypothalamus, hippocampus, and medulla-pons the content of IGF-I mRNA was similar to the amount found in total brain (Fig. 4) . In all CNS regions the length of the fragment protected from RNase digestion was 182 nucleotides, the size seen in peripheral tissues- (26) .
In contrast to IGF-I, and in agreement with recent observations of Soares et al. (13) , the abundance of IGF-II mRNA was relatively constant throughout the adult CNS, with minimal enrichment in the medulla-pons and cerebellum. Except for the corpus striatum, hypothalamus, and midbrain, all neuroanatomical regions analyzed contained at least half as much IGF-I mRNA as was found in total brain (Fig. 4) . The size of the protected doublet, 151-152 nucleotides, was identical to that seen in extraneural tissues. In general IGF-II mRNA was more prevalent than IGF-I mRNA in the CNS, as judged by the briefer autoradiographic exposure times required to generate bands of equal intensity.
Developmental Patterns of IGF Gene Expression in the Brain. It has been suggested that in rodents, IGF-I acts primarily as a postnatal growth hormone-dependent growthpromoting agent, whereas IGF-II may function analogously during fetal development (2, 3) . To determine whether a fetal-to-adult switch in IGF production occurs in the brain, as has been defined for other rat tissues (9-13, 36), we analyzed IGF mRNA content at various times during embyronic and postnatal life. IGF-I and IGF-1I mRNAs were both most abundant at the earliest point examined, day 14 of fetal development, declined by a factor of 2.5 by day 18, and declined to adult values by the first postnatal day (Fig. 5) . Both IGFs thus follow a similar developmental path in the CNS, with the highest levels of gene expression coinciding with early phases of neuronal growth.
To define the neural cell types responsible for biosynthesis of IGF-I and -II during fetal life, we assessed IGF mRNA production in primary cultures derived from day-17 embryonic brain, using conditions promoting either neuronal or glial survival. Both neurons and glia synthesize IGF-I mRNA after 1 week in culture. IGF-I mRNA levels are nearly 3-fold higher in astroglia than in neurons, when normalized for ,p-actin mRNA content (Fig. 6 ). In contrast, no IGF-II mRNA was detected in neuronal cultures. Only glial cultures contain measurable quantities of IGF-II mRNA.
DISCUSSION
Our data from RNA solution-hybridization studies support the proposal that IGF-I and -II are synthesized in the mammalian CNS (6) (7) (8) . We found that mRNAs for both growth factors are widely distributed in the nervous system, being produced throughout the brain and spinal cord of adult ;,.ad& rats and during embryogenesis. Despite the apparently similar developmental and regional patterns of biosynthesis for the two growth factor mRNAs in the CNS, IGF-I and -II are differentially expressed. IGF-I mRNA is concentrated in the olfactory bulb and in the cervical-thoracic spinal cord, and to a lesser degree in the midbrain and cerebellum. In the spinal cord, where IGF-I mRNA is 10 times more abundant than in whole brain, levels are -10% of those found in liver (Fig. 3) . In contrast, IGF-II mRNA is more evenly distributed throughout the CNS, but is 3-5 times less abundant in the corpus striatum and midbrain than in total brain. Steady-state levels of IGF-II mRNA in brain are >50 times higher than in adult liver (Fig. 4) . Although during brain development the two somatomedin mRNAs are expressed in parallel, with a decline in abundance from fetal day 14 until birth, the similar developmental profile probably reflects expression from different cell populations. IGF-I mRNA is synthesized by primary cultures derived from day-17 embryonic neurons and from embryonic astroglia. IGF-II mRNA appears to be produced almost exclusively by astoglial cultures and not by neuronal cells (Fig. 5 ).
Our observations expand upon studies performed in several laboratories regarding somatomedin synthesis in the CNS. IGF-II peptides of different molecular mass have been extracted from multiple areas of the human brain (6) , and IGF-II mRNA has been detected in several regions of the adult and fetal rat CNS (9) (10) (11) (12) (13) (14) (15) . By contrast, IGF-I was not found in adult human brain regions (6) but was isolated from fetal brain (7) . Small quantities of IGF-I also were detected by radioimmunoassay in adult rat brain (8) . IGF-I mRNA was detected in adult and fetal rodent CNS (9, (14) (15) (16) . In all tissues analyzed for IGF-I and IGF-I mRNA, including the brain, multiple hybridizing species were found (9) (10) (11) (12) (13) (14) (15) (16) (25) and from sensory and sympathetic neurons (23, 24) . The persistence of relatively high levels of IGF-II mRNA in the CNS into adult life contrasts with its more developmentally restricted expression in other rodent tissues (9-13, 39) and further substantiates the importance of IGF-II in the brain. In contrast, IGF-I, with its striking regional localization, may serve a more specialized purpose, particularly in the spinal cord and olfactory bulb of adult rats. In this context the relatively high concentration of IGF-I receptors in olfactory bulb (17) further underscores the importance of IGF-I in this neuroanatomical location. Our demonstration that IGF-I mRNA is produced by embryonic neurons, coupled with the ability of exogenous IGF-I to promote proliferation and differentiation of fetal rat cortical neurons in primary tissue culture (21) , also suggests that IGF-I may be involved as an autocrine growth factor in the CNS. Since, by alternative RNA splicing the IGF-I gene gives rise to distinct mRNAs encoding different proteins (29, 40) , it is conceivable that unique IGF-I-containing polypeptides may be synthesized in different regions of the CNS or at different developmental times to perform distinct functions. The availability of histochemical and other techniques for studying somatomedin gene expression and its regulation in discrete neuroanatomical regions will facilitate our understanding of the roles of IGF-I and IGF-II in the mammalian nervous system.
